2023
Authors: Fernández-Luis S, Lain MG, Serna-Pascual M, Domínguez-Rodríguez S, Kuhn L, Liberty A, Barnabas S, Lopez-Varela E, Otwombe K, Danaviah S, Nastouli E, Palma P, Cotugno N, Spyer M, Giannuzzi V, Giaquinto C, Violari A, Cotton MF, Nhampossa T, Klein N, Ramsagar N, van Rensburg AJ, Behuhuma O, Vaz P, Maiga AI, Oletto A, Naniche D, Rossi P, Rojo P, Tagarro A; EPIICAL Consortium
Published in: BioMed Central
2023
Authors: Ruggiero A, Pascucci GR, Cotugno N, Domínguez-Rodríguez S, Rinaldi S, Tagarro A, Rojo P, Foster C, Bamford A, De Rossi A, Nastouli E, Klein N, Morrocchi E, Fatou B, Smolen KK, Ozonoff A, Di Pastena M, Luzuriaga K, Steen H, Giaquinto C, Goulder P, Rossi P, Levy O, Pahwa S, Palma P; EPIICAL Consortium
Published in: Frontiers
2023
Authors: Domínguez-Rodríguez S, Serna-Pascual M, Oletto A, Barnabas S, Zuidewind P, Dobbels E, Danaviah S, Behuhuma O, Lain MG, Vaz P, Fernández-Luis S, Nhampossa T, Lopez-Varela E, Otwombe K, Liberty A, Violari A, Maiga AI, Rossi P, Giaquinto C, Kuhn L, Rojo P, Tagarro A; EPIICAL Consortium
Published in: Plos One
2023
Authors: Domínguez-Rodríguez S, Tagarro A, Foster C, Palma P, Cotugno N, Zicari S, Ruggiero A, de Rossi A, Dalzini A, Pahwa S, Rinaldi S, Nastouli E, Marcelin AG, Dorgham K, Sauce D, Gartner K, Rossi P, Giaquinto C, Rojo P
Published in: Frontiers
2023
Speaker: Morrocchi E
Presented at: CROI 2023
2022
Authors: Bréhin, Tagarro A, Domínguez-Rodríguez S, Kuhn L, Nhampossa T, Otwombe K, Janse van Rensburg A, Klein N, Lain MN, Maiga AI, Giaquinto C, Rossi P, Rojo P, EPIICAL Consortium
Presented at: AIDS 2022
2022
Authors: Dominguez Rodriguez S, Ballesteros Á, Kuhn L, Nhampossa T, Otwombe K, Shaun Barnabas S, Klein N, Lain M.G, Giaquinto C, Rossi P, Rojo P, Tagarro A, EPIICAL Consortium
Presented at: AIDS 2022
2022
Authors: Sinead E. Morris, Renate Strehlau, Stephanie Shiau, Elaine J. Abrams, Caroline T. Tiemessen, Louise Kuhn, Andrew J. Yates on behalf of the EPIICAL consortium and LEOPARD study teams
Published in: Plos Pathogens
2022
Authors: Ruggiero A, Pascucci G.R, Cotugno N, Domínguez-Rodríguez S, Rinaldi S, Tagarro A, Rojo P, Foster C, Bamford A, De Rossi A, Nastouli E, Klein N, Morrocchi E, Fatou B, Smolen K.K, Ozonoff A, Di Pastena M, Luzuriaga K, Steen H, Giaquinto C, Goulder P, Rossi P, Levy O, Pahwa S, Palma P, the EPIICAL Consortium
Published in: Frontiers in Immunology
2022
Authors: S Domínguez-Rodríguez, A Tagarro, C Foster, P Palma, N Cotugno, AD Rossi, A Dalzini, SG. Pahwa, E Nastouli, K Gärtner, AG Marcelin, P Rossi, C Giaquinto, P Rojo
Presented at: CROI 2022
2022
Authors: A Tagarro, S Domínguez-Rodríguez, L Kuhn, T Nhampossa, K Otwombe, AJv Rensburg, N Klein, MG Lain, AI. Maiga, C Brehin, C Giaquinto, P Rossi, P Rojo
Presented at: CROI 2022
2021
Authors: A Dalzini, G Ballin, S Dominguez-Rodriguez, P Rojo , M.R Petrara, C Foster, N Cotugno, A Ruggiero, E Nastouli, N Klein, S Rinaldi, S Pahwa, P Rossi, C Giaquinto, P Palma , A De Rossi1, and on behalf of EPIICAL Consortium
Published in: Journal of the International AIDS Society
2021
Authors: Gärtner K, Byott M, Heaney J, Pagliuzza A, Spyer M.J Frampton D, Rossi A.D, Palmas P, Giaquinto C, Conejo P.R, Foster C, Rossi P, Klein N, Chomont N, Nastouli E, for the EPIICAL consortium
Presented at: Keystone symposia on molecular and cellular biology
2021
Authors: M Doria, S Zicari, N Cotugno, S Domínguez-Rodríguez, A Ruggiero, GR Pascucci, A Tagarro, PR Conejo, E Nastouli, K Gärtner, M Cameron, B Richardson, Ce Foster, SL Williams, S Rinaldi, AD Rossi, C Giaquinto, P Rossi, S Pahwa, P Palma, for the EPIICAL consortium
Published in: Journal of the International Aids Society
Abstract
Introduction HIV infection causes pathological changes in the natural killer (NK) cell compartment that can be only partially restored by antiretroviral therapy (ART).
2020
Authors: Foster C, Domínguez-Rodríguez S, Tagarro A, et al. For the Early Treated Perinatally HIV Infected Individuals: Improving Children’s Actual Life (EPIICAL) Consortium
Published in: J Pediatr Infect Dis Soc. 2020 2020 Jul 17;piaa071
Background Strategies aimed at antiretroviral therapy (ART)–free remission will target individuals with a limited viral reser- voir.
2020
Authors: De Rossi A, Dalzini A, Ballin G, Dominguez-Rodriuguez S, Rojo P, Foster C, Palma P, Sessa L, Nastouli E, Pahwa S, Rossi P, Giaquinto C, EPIICAL Consortium
Published in: 23rd International AIDS Conference, July 6th-10th, 2020
Background: HIV infection is linked to premature senescence, with increased risk of aging-associated illnesses. Early ART has been associated with a reduced HIV reservoir in HIV-perinatally infected children (PHIV),
2020
Authors: Ruggiero A, Cotugno N, Domínguez-Rodríguez S, Zicari S, Rinaldi S, Zangari P, Tagarro A, Foster C, De Rossi A, Nastouli E, Luzuriaga K, Giaquinto C, Rossi P, Pawha S, Palma P, on behalf of the EPIICAL consortium.
Published in: 23rd Virtual International AIDS Conference, July 6th-10th, 2020
Background The role of T-bet, an immune factor involved in adaptative and innate response,
2020
Authors: Domínguez-Rodríguez S, Tagarro A, Serna Pascual M, Otwombe K, Violari A, Fernández S, Nhampossa T, Lain M, Vaz P , Behuhuma NO, Danaviah S, Dobbels E, Barnabas S, Cotugno N, Zangari P, Palma P, Oletto A, Nardone A, Nastouli E, Spyer M, Kuhn L, Rossi P, Giaquinto C, Rojo P on behalf of EPIICAL consortium.
Published in: 23rd international AIDS Conference, July 6th-10th 2020
Background In perinatally HIV infected children,
2020
Authors: Palma P, McManus M, Cotugno N, Rocca S, Rossi P, Luzuriaga K
Published in: Lancet HIV. 2020;7(5):e359-e365
Abstract Several assays have been developed to measure and characterise the replication-competent HIV-1 reservoir, which constitutes the barrier to cure. To date, the application of these assays to studies in children and in limited-resource settings has been minimal,
2020
Authors: Dhummakupt A, Rubens JH, Andeson T, et al.
Published in: JCI Insight. 2020;5(4)
Abstract The HIV latent reservoir in resting memory CD4+ T cells precludes cure. Therapeutics to reactivate and eliminate this reservoir are in clinical trials in adults, but not yet in pediatric populations. We determined, ex vivo,
2020
Authors: Dhummakupt A, Reubens JH, Anderson T, et al.
Published: Poster presented at 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
Abstract The HIV latent reservoir in resting memory CD4+ T cells prevents cure. Novel therapies to reactivate and eliminate the reservoir are in clinical trials in adults, but not yet in pediatric populations.
2020
Authors: Schröter J, Anelone A, Yates A, de Boer RJ; on behalf of the EPIICAL Consortium
Published in: J Acquir Immune Defic Syndr. 2020;83(5):522-529
Background Interventions aiming for an HIV cure would benefit from rapid elimination of virus after the onset of antiretroviral therapy (ART), by keeping the latent HIV reservoir small.
2020
Authors: Dominguez-Rodriguez S, Rojo P, Lain MG, Barnabas S, Lopez-Varela E, Otwombe K, Danaviah S, Nastouli E, Serna-Pasqual M, Gianuzzi V, Giaquointo C, Kuhn L, Tagarro A on behalf of the EPIICAL Consortium
Published in: 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
2020
Authors: Zicari S, Doria M, Domínguez-Rodríguez S, Cotugno N, Tagarro A, Rojo P, Nastouli E, Gartner K, Klein N, Foster C, Pahwa S, De Rossi A, Giaquinto C, Rossi P, Palma P, for the EPIICAL consortium
Published in: 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
2020
Authors: Tagarro A, Domínguez-Rodríguez S, Violari A, Cotton M, Mhampossa T, Klein N, Ramsagar N, Van Rensburg AJ, Behuhuma O, Vaz P, Oletto A, Palma P, Rossi P, Rojo P, on behalf of the EPIICAL Consortium
Published in: 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
2020
Authors: Gärtner K, Gkouleli T, Byott M, Heaney J, Spyer MJ, DeRossi A, Persaud D, Palma P, Giaquinto C, Rojo P, Foster C, Marcelin AG, Rossi P, Nastouli E, for the EPIICAL consortium
Published in: 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
2020
Authors: Gärtner K, Gkouleli T, Heaney J, Grant P, Dominguez-Rodriguez S, Busby E, O’Sullivan D, Spyer MJ, Foster C, Rojo P, Persaud D, DeRossi A, Huggett J, Nastouli E, for the EPIICAL consortium
Published in: 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
2020
Authors: Rinaldi S, Pallikkuth S, de Armas L, Pahwa R, Dominguez S, Cotugno N, Rojo Conejo P, Nastouli E, Gartner K, Klein N, Foster C, De Rossi A, Carlo Giaquinto C, Rossi P, Palma P, Pahwa S and EPIICAL Consortium
Published in: 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
2020
Authors: Lain MG, Vaz P, Ismael N, Cantarutti A, Porcu G, Palma P, Cotugno N, Bila D, Rinaldi S, Pallikkuth S, Pahwa R, Taibo E, Esmeralda Karajeanes E, Giaquinto C, Pahwa S.
Published in: 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
2020
Authors: Morris SE, Dziobek-Garrett L, Yates AJ and the EPIICAL consortium
Published in: BMC Bioinformatics 2020;21(1):52
Background HIV/AIDS is responsible for the deaths of one million people every year. Although mathematical modeling has provided many insights into the dynamics of HIV infection, there is still a lack of accessible tools for researchers unfamiliar with modeling techniques to apply them to their own clinical data.
2020
Authors: Cotugno N, Morrocchi E, Rinaldi S, et al; EPIICAL Consortium.
Published in: AIDS. 2020 Feb 3.
Objective To investigate long-term persistence of HIV-specific lymphocyte immunity in perinatally HIV-infected children treated within the first year of life.
Design Twenty perinatally HIV-infected children who received ART therapy within the first year of life (early treated) and with stable viral control (>5 years) were grouped according to their serological response to HIV.
2020
Authors: Rinaldi S, Pallikkuth S, Cameron M, et al.
Published in: J Immunol. 2020 Feb 1;204:540-549
Abstract Early initiation of antiretroviral therapy (ART) in vertically HIV-infected children limits the size of the virus reservoir, but whether the time of treatment initiation (TI) can durably impact host immune responses associated with HIV infection is still unknown.
2019
Authors: S. Rinaldi, V. Dinh, S. Pallikkuth, L. De Armas, R. Pahwa, N. Cotugno, E. Nastouli, C. Foster, P. Palma, S. Pahwa
Published in: Poster presented at 9th International Workshop on HIV Persistence during Therapy; December, 2019; Miami, FL
Background: Curative strategies for HIV will need to eliminate the replication competent latent reservoir.
2019
Authors: Domínguez-Rodríguez S, Tagarro A. Palma P, et al.
Published in: JAIDS 2019;82(5):483-490
2019
Authors: Schröter J.
Published in: Poster presented at 4th Workshop on Virus Dynamics, October 21st-23rd, 2019 -Paris, FR
2019
Authors: Gärtner K, Gkouleli T, Heaney J, et al; on behalf of the EPIICAL consortium
Published: Poster presented at HIV Cure and Reservoir Symposium, September, 16th-20th, 2019 -Ghent, BE
2019
Authors: Foster C, Dominguez S, Tagarro A, Nastouli E, Gkouleli R, Heaney J, PalmaP, Rossi P, Giaquinto C, Rojo P
Published: 10th IAS Conference on HIV Science, July 21rd-24th 2019, Mexico City
Background Future strategies aimed at achieving antiretroviral therapy (ART)-free HIV remission are likely to target individuals with a limited size of viral reservoir.
2019
Authors: Heaney J, Busby E, Gärtner K, Grant P, Spyer MJ, O’Sullivan DM, Gkouleli T, Marcelin AG, Pillay D, Foster C, Rojo P, Palma P, Muñoz Fernández MA, deRossi A, Huggett JF, Nastouli E
Published: International Workshop on HIV Pediatrics, July 19th-20th, 2019. P_102
Background Despite effective antiretroviral therapy(ART), HIV persists as integrated provirus generating latent viral reservoirs even in the absence of detectable plasma viremia.
2019
Authors: Tagarro A, Dominguez Rodriguez S, Puthanakit T, et al.
Published: Oral presentation at 27th Conference on Retroviruses and Opportunistic Infections, March 4th-7th, 2019 – Seattle, WA
Abstract: Early antiretroviral therapy (ART) in children is associated with better clinical and virological outcome. Few data are available about long-term outcome of children starting ART in the neonatal period.
2019
Authors: Schröter J.
Published: Oral presentation at 26th International HIV Dynamics & Evolution, March 24th-27th, 2019, Cascais, PT
2019
Authors: Chan MK, Goodall R, Judd A, et al.
Published in: Aids. 2019; 33(7):1155-1165
Objective To identify predictors of faster time to virological suppression among infants starting combination antiretroviral therapy (cART) early in infancy.
Design Cohort study of infants from Europe and Thailand included in studies participating in the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC).
2018
Authors: Cotugno N, Morrocchi E, Pepponi I, et al.
Abstract Early initiation of ART in HIV vertically infected infants influences specific immunity by limiting Ag exposure and reducing the viral reservoir size. Currently these patients represent ideal candidates for testing immune therapeutic strategies towards HIV-remission.
2018
Authors: Rinaldi S, Cotugno N, Pallikkuth S, Pahwa R, Palma P, Pahwa S
Abstract Early initiation of antiretroviral therapy (ART) in vertically HIV-infected children provides an opportunity to limit the size of HIV reservoir. However, how the time of ART initiation impacts host HIV-specific immune responses is still poorly understood.
2018
Authors: Violari A, Chan M, Otwombe KN, Panchia R, Jean-Philippe P, Gibb D, Cotton M, Babiker A
2018
Authors: Cameron M, Rinaldi S, Richardson B, Cotugno N, Williams S, Pallikkuth S, de Armas LR, Cameron C, Pahwa R, Palma P, Pahwa S
Published: 25th Conference on Retroviruses and Opportunistic Infections, March 4th – 7th, 2018 – Boston. P_868
Abstract The study explores the impact of early ART on host immune response looking at HIV-specific CD4 T cell functionality and host transcriptome analysis.
2018
Authors: Chan M, Tagarro A, Zangari P, Ferns B, Foster C, De Rossi A, Nastouli E, Ángeles Muñoz-Fernández M, Gibb D, Rossi P, Giaquinto C, Babiker A , Palma P, Rojo Conejo P
Published: 25th Conference on Retroviruses and Opportunistic Infections, March 4th – 7th, 2018 – Boston. P_ 866
Abstract The study focused on the determinants of low viral reservoir in a large cohort of European early treated HIV-1 infected children.
2018
Authors: Rocca S, Zangari P, Cotugno N, et al.
Published in: J Pediatric Infect Dis Soc.2018; 28. doi:10
Background Assays to estimate human immunodeficiency virus (HIV) reservoir size require large amounts of blood, which represents a drawback especially in pediatric settings. We investigated whether HIV-antibody repertoire could estimate the viral reservoir size. Moreover, we assessed the magnitude of HIV-antibody response as a predictor of time of antiretroviral therapy (ART) initiation.
2018
Authors: Cotugno N, Morrocchi E, Pepponi I, Rocca S, Cameron M, Rinaldi S, Di Cesare S, Pallikkuth S, Bernardi S, Klein N, Ananworanich J, Rossi P, Pahwa S, Palma P
Published: 25th Conference on Retroviruses and Opportunistic Infections, March 4th – 7th, 2018 – Boston. P_ 866
Abstract This fascinating study investigates whether HIV specific B cells persist in seronegative HIV infected seronegative patients and what are the associated gene signatures after re-encountering the virus.
2018
Authors: Tagarro A, Chan M, Zangari P, et al; on behalf of the EPIICAL Consortium
Published in: J Acquir Immune Defic Syndr. 2018;79(2):269-276
Background Future strategies aiming to achieve HIV-1 remission are likely to target individuals with small reservoir size.
Setting We retrospectively investigated factors associated with HIV-1 DNA levels in European,
2018
Authors: Zangari P, Palma P, Cotugno N, et al.
Published in: J Virus Erad.2018;4: 51–54
Abstract: The first EPIICAL General Assembly meeting was held in an atmosphere of growing optimism. Many novel and exciting proposals for HIV research studies were discussed and are described above. The consortium aims to maintain this integrated developmental research on NDMTs,